Paranasal Mucormycosis: A Literature Review

Jump To References Section

Authors

  • Department of Periodontics and Implantology, Santosh Dental College & Hospital, Ghaziabad, Delhi NCR – 201009 ,IN
  • Department of Periodontics and Implantology, Santosh Dental College & Hospital, Ghaziabad, Delhi NCR – 201009 ,IN
  • Department of Periodontics and Implantology, Santosh Dental College & Hospital, Ghaziabad, Delhi NCR – 201009 ,IN

DOI:

https://doi.org/10.18311/jpfa/2021/28091

Keywords:

COVID-19, Facts, Mucormycosis, Opprotunistic Infection
Mucormycosis

Abstract

Mucormycosis has wreaked havoc amongst the COVID-19 pandemic, crippling the patients already battling the virus. It is therefore of utmost importance that the facts be separated from the myths in order to tackle this problem from the roots. The basis of this current review article to compile all the information regarding the facts about mucormycosis in one place so as to get a better understanding of the disease process and hence work towards reducing patient morbidity and mortality.

Published

2021-12-16

How to Cite

Nautiyal, A., Bali, S., & Aggarwal, P. (2021). Paranasal Mucormycosis: A Literature Review. Journal of Pierre Fauchard Academy (India Section), 35(3), 106–110. https://doi.org/10.18311/jpfa/2021/28091

Issue

Section

Literature Article

 

References

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2020; S0735–6757(20): 30826–30833.

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020; 6: 265.

Muzyka BC, Epifanio RN. Update on oralfungal infections. Dental clinics of North America. 2013; 57(4): 561–81.

Brondfield S, Kaplan L, Dhaliwal G. Palatal mucormycosis. J. Gen. Intern. Med. 2018; 33(10): 1815.

Rajendra Santosh AB, Muddana K, Bakki SR. Fungal Infections of Oral Cavity: Diagnosis, Management, and Association with COVID-19. SN Compr Clin Med. 27 Mar 2021: 1–12. https://doi.org/10.1007/s42399-02100873-9. Epub ahead of print. PMID: 33817556; PMCID: PMC8003891.

Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19 a meta-analysis. JAMA. 2020; 324(13): 1330–1341.

Kumar G, Adams A, Hererra M, Rojas ER, Singh V, Sakhuja A, et al. Predictors and outcomes of haisin COVID-19 patients. Int J Infect Dis. 2020; 104(3): 287–92.

Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, et al. IL-6 inhibition in critically Ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne). 2020; 7: 583897.

Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, Savio J, Sethuraman N, Madan S, Shastri P, Thangaraju D, Marak R, Tadepalli K, Savaj P, Sunavala A, Gupta N, Singhal T, Muthu V, Chakrabarti A; MucoCovi Network. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis. 4 Jun 2021; 27(9). https://doi.org/10.3201/eid2709. 210934. Epub ahead of print. PMID: 34087089.

Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020; 12(9): e10726

Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. J Mycol Med. 2020; 30: 100971

Revannavar SM, PSS, Samaga L, VKV. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 27 Apr 2021; 14(4): e241663. https://doi. org/10. 1136/bcr-2021-241663. PMID: 33906877; PMCID: PMC8088249.

Hingad N, Kumar G, Deshmukh R. Oral mucormycosis causing necrotizing lesion in a diabetic patient: a case report. International Journal of Oral and Maxillofacial Pathology. 2012; 3(3).

DeShazo RD. Fungal sinusitis. Am J Med Sci. 1998; 316: 39–44

Ferguson BJ. Definitions of fungal rhinosinusitis. Otolaryngol Clin North Am. 2000; 33: 227–35

Chakrabarti A, Denning DW, Ferguson BJ, Ponikau J, Buzina W, Kita H et al. Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope. 2009; 119: 1809-18.

Scheckenbach K, Cornely O, Hoffmann TK, Engers R, Bier H, Chaker A et al. Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx. 2010; 37: 322-8.

Vairaktaris E, Moschos MM, Vassiliou S, Baltatzis S, Kalimeras E, Avgoustidis D et al. Orbital cellulitis, orbital subperiosteal and intraorbital abscess. Report of three cases and review of the literature. J Craniomaxillofac Surg. 2009; 37: 132-6.

Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses. 2007; 50: 132-6.

Munir N, Jones NS. Rhinocerebral mucormycosis with orbital and intracranial extension: a case report and review of optimum management. J Laryngol Otol. 2007; 121: 1925.

Gillespie MB, O’Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am. 2000; 33: 323-34.

Ballester DG, González-García R, García CM, Ruiz-Laza L, Gil FM. Mucormycosis of the head and neck: report of five cases with different presentations. J Craniomaxillofac Surg. 2012; 40: 584–91.

Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti A, Agarwal R. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. May 2021; 186(2): 289–298. https://doi. org/10.1007/s11046-021-00528-2. Epub 2021 Feb 5. PMID: 33544266; PMCID: PMC7862973.

Muthu V, Agarwal R, Dhooria S, Sehgal IS, Prasad KT, Aggarwal AN, et al. Has the mortality from pulmonary mucormycosis changed over time? a systematic review and meta-analysis. Clin Microbiol and Infect. 2021.

Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst H-A, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R. Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clin Infect Dis. 2007; 44(10): 1289–1297.

Reddy S, Kumar K, Sekhar C, Reddy R. Oral mucormycosis: need for early diagnosis!! J Dr NTR Univ Health Sci. 2014; 3(2): 145–7.

Benites BM, Fonseca FP, Parahyba CJ, Arap SS, Novis YA, Fregnani ER. Extensive oral mucormycosis in a transplanted patient. The J Craniomaxillofac Surg. 2017; 28(1): e4–5.

DeShazo RD, Chapin K, Swain RE. Fungal sinusitis. N Engl J Med 1997; 337: 254–9. https://doi. org/10. 1056/ NEJM199707243370407

Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013; 98(4): 492–504. https://doi.org/10.3324/haematol.2012.065110

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clinical Infectious Diseases. 2012; 54(suppl_1): S23–S34. https://doi.org/10.1093/cid/cir866

Morace G, Borghi E. Invasive mold infections: virulence and pathogenesis of mucorales. Int. J. Microbiol. 2011; 2012. https://doi.org/10.1155/2012/349278

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the european confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019; 19(12): e405– 21.

Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020; 26(7): 9–15. https://doi.org/10.1016/j.cmi.2019.11.021

Pandey N, Kaushal V, Puri GD, Taneja S, Biswal M, Mahajan P, et al. Transforming a general hospital to an infectious disease hospital for COVID-19 over 2 weeks. Front Public Health. 2020; 8: 382. https://doi.org/10.3389/fpubh.2020. 00382

Morace G, Borghi E. Invasive mold infections: virulence and pathogenesis of mucorales. Int. J. Microbiol. 2011; 2012. https://doi.org/10.1155/2012/349278

Cornely O, Arikan-Akdagli S, Dannaoui E, Groll A, Lagrou K, Chakrabarti A, et al. ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection. 2014; 20: 5–26. https://doi.org/10.1111/1469-0691.12371

Prenissl J, Jaacks LM, Mohan V et al. Variation in health system performance for managing diabetes among states in India: a cross–sectional study of individuals aged 15 to 49 years. BMC Med2019; 17:92. https://doi.org/10.1186/s12916-019-1325-6

Saldanha M, Reddy R, Vincent MJ. Title of the Article: Paranasal Mucormycosis in COVID-19 Patient. Indian J Otolaryngol Head Neck Surg. 22 Apr 2021:1–4. https://doi. org/10.1007/s12070-021-02574-0. Epub ahead of print. PMID: 33903850; PMCID: PMC8060684.